Evotec Presents Plan Targeting EUR 75 Million in Annual Run-Rate Cost Savings by End-2027

By Public Technologies
  • Evotec signed a deal to sell its Toulouse biologics site to Sandoz for approximately US$ 350 million upfront, including technology licensing.
  • The agreement includes more than US$ 300 million in license, milestone and development revenue commitments for 2026-2028.
  • Royalties on 10 biosimilars offer additional revenue potential beyond 2028; six are in technical development.
  • The Horizon restructuring targets approximately 800 job cuts, reducing the global footprint from 14 sites to 10.
  • Expected annual run-rate savings reach approximately EUR 75 million by end-2027, against approximately EUR 100 million in total cash costs.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evotec SE published the original content used to generate this news brief on November 06, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk